The “old” and the “new” antibiotics for MDR gram-negative pathogens: for whom, when, and how
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …
significant challenges in the treatment of healthcare associated infections. An important …
Treatment of infections due to MDR Gram-negative bacteria
M Bassetti, M Peghin, A Vena, DR Giacobbe - Frontiers in medicine, 2019 - frontiersin.org
The treatment of multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in
critically ill patients presents many challenges. Since an effective treatment should be …
critically ill patients presents many challenges. Since an effective treatment should be …
New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review
P. aeruginosa is still one of the most threatening pathogens responsible for serious hospital-
acquired infections. It is intrinsically resistant to many antimicrobial agents and additional …
acquired infections. It is intrinsically resistant to many antimicrobial agents and additional …
Resistance to novel β-lactam–β-lactamase inhibitor combinations: the “price of progress”
KM Papp-Wallace, AR Mack, MA Taracila… - Infectious Disease …, 2020 - id.theclinics.com
As a class, the b-lactams are the most commonly prescribed and clinically dependable
antimicrobials in the United States, representing more than 65% of injected antibiotic …
antimicrobials in the United States, representing more than 65% of injected antibiotic …
Old and new beta-lactamase inhibitors: molecular structure, mechanism of action, and clinical use
The β-lactams have a central place in the antibacterial armamentarium, but the increasing
resistance to these drugs, especially among Gram-negative bacteria, is becoming one of the …
resistance to these drugs, especially among Gram-negative bacteria, is becoming one of the …
The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections
KM Papp-Wallace - Expert opinion on pharmacotherapy, 2019 - Taylor & Francis
ABSTRACT Introduction: Antimicrobial resistance in Gram-negative pathogens is a
significant threat to global health. β-Lactams (BL) are one of the safest and most-prescribed …
significant threat to global health. β-Lactams (BL) are one of the safest and most-prescribed …
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience
M Bassetti, N Castaldo, A Cattelan, C Mussini… - International journal of …, 2019 - Elsevier
This study describes the largest clinical experience using ceftolozane/tazobactam (C/T) for
different Pseudomonas aeruginosa infections. A retrospective study was performed at 22 …
different Pseudomonas aeruginosa infections. A retrospective study was performed at 22 …
β-lactam/β-lactamase inhibitor combinations: an update
KHME Tehrani, NI Martin - Medchemcomm, 2018 - pubs.rsc.org
Antibiotic resistance caused by β-lactamase production continues to present a growing
challenge to the efficacy of β-lactams and their role as the most important class of clinically …
challenge to the efficacy of β-lactams and their role as the most important class of clinically …
Extended-spectrum β-lactamases (ESBL): challenges and opportunities
The rise of antimicrobial resistance, particularly from extended-spectrum β-lactamase
producing Enterobacteriaceae (ESBL-E), poses a significant global health challenge as it …
producing Enterobacteriaceae (ESBL-E), poses a significant global health challenge as it …
Carbapenem-sparing strategies for ESBL producers: when and how
I Karaiskos, H Giamarellou - Antibiotics, 2020 - mdpi.com
Extended spectrum β-lactamase (ESBL)-producing bacteria are prevalent worldwide and
correlated with hospital infections, but they have been evolving as an increasing cause of …
correlated with hospital infections, but they have been evolving as an increasing cause of …